{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:52:57Z","timestamp":1776873177725,"version":"3.51.2"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T00:00:00Z","timestamp":1656201600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jilin Province Health and Health Technology Innovation Project","award":["2020J109"],"award-info":[{"award-number":["2020J109"]}]},{"name":"Jilin Province Health and Health Technology Innovation Project","award":["2021LC058"],"award-info":[{"award-number":["2021LC058"]}]},{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","award":["2020J109"],"award-info":[{"award-number":["2020J109"]}],"id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","award":["2021LC058"],"award-info":[{"award-number":["2021LC058"]}],"id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oncology"],"published-print":{"date-parts":[[2022,6,26]]},"abstract":"<jats:p>Objective. To investigate the clinical efficacy and safety of albumin paclitaxel combined with intrapleural bevacizumab\u2009+\u2009lobaplatin for patients with non-squamous non-small cell lung cancer (NS-NSCLC) with malignant pleural effusion (MPE) and analyze prognostic factors. Methods. A total of 126 NS-NSCLC patients were included in the study. Control group with 64 cases received intrapleural infusion of lobaplatin\u2009+\u2009intravenous albumin paclitaxel, and treatment group with 62 cases received additional intrapleural bevacizumab perfusion. Analysis was performed by collecting data about MPE, progression-free survival (PFS), overall survival (OS), and scores of quality of life. Results. In the treatment and control groups, objective response rate (ORR) was 51.6% and 31.3% (\u03c72\u2009=\u20095.39,<jats:inline-formula><a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><a:mi>P<\/a:mi><a:mo>=<\/a:mo><a:mn>0.02<\/a:mn><\/a:math><\/jats:inline-formula>), and disease control rate (DCR) was 91.9% and 71.9% (\u03c72\u2009=\u20098.49,<jats:inline-formula><c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><c:mi>P<\/c:mi><c:mo>=<\/c:mo><c:mn>0.004<\/c:mn><\/c:math><\/jats:inline-formula>), respectively. The main adverse reactions (\u2265grade 3) in the treatment group were thrombocytopenia, peripheral neurotoxicity, proteinuria, neutropenia, and nausea\/vomiting, and in the control group, they were weakness, nausea\/vomiting, anemia, and peripheral neurotoxicity. In the control and treatment groups, the median PFS was 6.2 (95% confidence interval (CI): 5.86\u20136.56) and 5.1 (95% CI: 4.956\u20135.191), and the median OS was 14.4 (95% CI: 12.681\u201316.113) and 10.6 months (95% CI: 8.759\u201312.391). The score of quality of life for treated patients was significantly higher than those before treatment and the control group, and the parameters included general health status (GH), role physical (RP), body pain (BP), social function (SF), and vitality (VT); pH, CD4+\/CD8+ values, and vascular endothelial growth factor (VEGF) in the pleural effusion significantly affected the PFS and OS (<jats:inline-formula><e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\"><e:mi>P<\/e:mi><e:mo>&lt;<\/e:mo><e:mn>0.05<\/e:mn><\/e:math><\/jats:inline-formula>). Bevacizumab administration in patients with bloody pleural effusion did not increase the risk of pleural hemorrhage. Conclusion. The combination of albumin paclitaxel and intrapleural bevacizumab\u2009+\u2009lobaplatin is effective and may reverse the adverse events in patients with NS-NSCLC and MPE. The change of CD4+\/CD8+ ratio before and after treatment is an independent and prognostic factor for patients with NS-NSCLC and MPE.<\/jats:p>","DOI":"10.1155\/2022\/5901450","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T03:18:22Z","timestamp":1656299902000},"page":"1-11","source":"Crossref","is-referenced-by-count":5,"title":["Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab\u2009+\u2009Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer"],"prefix":"10.1155","volume":"2022","author":[{"given":"Junjie","family":"Hou","sequence":"first","affiliation":[{"name":"Medical College, Yanbian University, Yanji, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuguang","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"General Surgery of the First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7086-5750","authenticated-orcid":true,"given":"Zhaoxue","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Secretory Metabolism, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhuo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Jilin Province People\u2019s Hospital, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-0576","authenticated-orcid":true,"given":"Ningyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Medical College, Yanbian University, Yanji, China"},{"name":"Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"10027","key":"1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"R. S. Herbst","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"2","first-page":"468","article-title":"Observation of herapeutic effect about advanced non-small lung cancer treated with apatinib mesylate tablets","volume":"24","author":"H. Cao","year":"2017","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"issue":"5","key":"3","first-page":"335","article-title":"Analysis of DC-CIK MDT clinical effect of treatment of advanced non-small cell lung cancer","volume":"23","author":"W. D. Guo","year":"2016","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"issue":"1","key":"4","first-page":"17","article-title":"Clinical trial of bevacizumab adjuvant conventional chemotherapy in the treatment of the non-small cell lung cancer","volume":"35","author":"L. Xing","year":"2019","journal-title":"The Chinese Journal of Clinical Pharmacology"},{"issue":"9","key":"5","first-page":"56","article-title":"Effect of application of markers and immune function of patients with tumor of erlotinib combined with Addie injection in non-small cell lung cancer","volume":"24","author":"F. Wen","year":"2018","journal-title":"Journal of Hainan Medical University"},{"issue":"4","key":"6","first-page":"272","article-title":"Application of bevacizumab in non-small cell lung cancer","volume":"20","author":"P. Xu","year":"2017","journal-title":"Chinese Journal of Lung Cancer"},{"issue":"1","key":"7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"52","author":"A. C. Bibby","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"1","key":"8","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-022-10318-5","article-title":"Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types","volume":"12","author":"H. Y. Seo","year":"2022","journal-title":"Scientific Reports"},{"issue":"4","key":"9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MCP.0b013e32832c6a8a","article-title":"Treatment options for malignant pleural effusion","volume":"15","author":"A. I. Musani","year":"2009","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"2","key":"10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Y. Liu","year":"2022","journal-title":"Nature Nanotechnology"},{"issue":"3","key":"11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3892\/ijo.2021.5174","article-title":"Novel therapies for malignant pleural effusion: anti angiogenic therapy and immunotherapy (review)","volume":"58","author":"D. He","year":"2021","journal-title":"International Journal of Oncology"},{"key":"12","first-page":"2939","article-title":"Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion","volume":"36","author":"M. Tamiya","year":"2016","journal-title":"Anticancer Research"},{"key":"13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2016.07.003","article-title":"A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: north east Japan study group trial NEJ013A","volume":"99","author":"K. Usui","year":"2016","journal-title":"Lung Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","article-title":"Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion","volume":"30","author":"M. Tamiya","year":"2013","journal-title":"Medical Oncology"},{"issue":"1","key":"15","first-page":"67","article-title":"Standards for the diagnosis and treatment of primary lung cancer in China (2015 edition)","volume":"37","author":"X. Y. Zhi","year":"2015","journal-title":"Chinese Journal of Oncology"},{"key":"16","first-page":"394","article-title":"Management of malignant pleural effusions","volume":"56","author":"S. A. Sahn","year":"2001","journal-title":"Monaldi Archives for Chest Disease"},{"issue":"18","key":"17","first-page":"2109","article-title":"Research progress of immune checkpoint inhibitors combined with anti-angiogenic drugs in the treatment of advanced non-squamous cell non-small cell lung cancer","volume":"17","author":"Z. Y. Xu","year":"2019","journal-title":"Oncology Progress"},{"issue":"24","key":"18","first-page":"60","article-title":"Clinical observation of apatinib combined with first-line chemotherapy in the treatment of driver gene-negative advanced non-squamous non-small cell lung cancer (report of 3 cases)","volume":"59","author":"X. F. Liang","year":"2019","journal-title":"Shandong Medical Journal"},{"issue":"8","key":"19","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ijc.31175","article-title":"Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced non-squamous non-small cell lung cancer: a network meta-analysis","volume":"142","author":"S. Zhao","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"8","key":"20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first- line therapy for nonsquamous non- small- cell lung cancer: AVAiL","volume":"27","author":"M. Reck","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"Beyond: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"C. Zhou","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cllc.2017.01.004","article-title":"Antiangiogenic therapy in advanced non-small-cell lung cancer: a meta-analysis of phase III randomized trials","volume":"18","author":"J. Raphael","year":"2017","journal-title":"Clinical Lung Cancer"},{"issue":"14","key":"23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s40265-016-0628-6","article-title":"Second-line treatment of non-small cell lung cancer: new developments for tumours not harbouring targetableoncogenic driver mutations","volume":"76","author":"P. C. Barnfield","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2015.05.022","article-title":"A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN oncology group 0110)","volume":"89","author":"K. Nishino","year":"2015","journal-title":"Lung Cancer"},{"issue":"8","key":"25","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1007\/s13277-016-5031-0","article-title":"A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)","volume":"37","author":"R. Quan","year":"2016","journal-title":"Tumor Biology"},{"issue":"28","key":"26","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2217\/fon-2017-0302","article-title":"Bevacizumab in advanced lung cancer: state of the art","volume":"13","author":"S. Assoun","year":"2017","journal-title":"Future Oncology"},{"key":"27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-108-3-345","article-title":"Pleural fluid pH in malignant effusions: diagnostic, prognostic and therapeutic implications","volume":"108","author":"S. A. Sahn","year":"1988","journal-title":"Annals of Internal Medicine"},{"key":"28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1378\/chest.104.5.1482","article-title":"Survival andtalc pleurodesis in metastatic pleural carcinoma revisited:report of 125 cases","volume":"104","author":"A. Sanchez-Armengol","year":"1993","journal-title":"Chest"},{"key":"29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1183\/09031936.05.00037004","article-title":"Vascular endothelial growth factor in pleural effusions of different origin","volume":"25","author":"U. Sack","year":"2005","journal-title":"European Respiratory Journal"},{"key":"30","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and apotential target for diagnosis and therapy","volume":"20","author":"H. F. Dvorak","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"31","first-page":"1129","article-title":"Levels of vascular endothelial growthfactor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of aprospective study","volume":"35","author":"I. Gkiozos","year":"2005","journal-title":"Anticancer Research"},{"key":"32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1183\/09031936.93.01040337","article-title":"Lymphocyte subsets in peripheral blood and pleural fluid","volume":"1","author":"G. Lucivero","year":"1988","journal-title":"European Respiratory Journal"},{"key":"33","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1378\/chest.103.6.1732","article-title":"Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion","volume":"103","author":"K. Takahashi","year":"1993","journal-title":"Chest"},{"issue":"10","key":"34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"D. I. Gabrilovich","year":"1996","journal-title":"Nature Medicine"}],"container-title":["Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/5901450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/5901450.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/5901450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T16:48:00Z","timestamp":1675961280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jo\/2022\/5901450\/"}},"subtitle":[],"editor":[{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,26]]},"references-count":34,"alternative-id":["5901450","5901450"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5901450","relation":{},"ISSN":["1687-8469","1687-8450"],"issn-type":[{"value":"1687-8469","type":"electronic"},{"value":"1687-8450","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,26]]}}}